	Application No.	Applicant(s)		
Notice of Allowability	10/012,202	HIRSH, MARK		
	Examiner	Art Unit		
	Humera N Sheikh	1615		
The MAILING DATE of this communication appeal all claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in or other appropriate comming IGHTS. This application is:	n this application. If not incluunication will be mailed in du	uded ue course. THIS	
1. This communication is responsive to 19 February 2004.				
2. ⊠ The allowed claim(s) is/are <u>1-29</u> .				
3. The drawings filed on are accepted by the Examine	er.			
4. Acknowledgment is made of a claim for foreign priority una) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority do International Bureau (PCT Rule 17.2(a)). * Certified copies not received:	e been received. e been received in Application	on No	cation from the	
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		e a reply complying with the	requirements	
5. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which giv			NOTICE OF	
 CORRECTED DRAWINGS (as "replacement sheets") mu (a) including changes required by the Notice of Draftspers 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR reach sheet. Replacement sheet(s) should be labeled as such in 	son's Patent Drawing Revie 's Amendment / Comment of 1.84(c)) should be written on	r in the Office action of	the back) of	
7. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT	osit of BIOLOGICAL MAT FOR THE DEPOSIT OF BI	ERIAL must be submitted OLOGICAL MATERIAL.	I. Note the	
Attachment(s)	5 □ Notice of I	nformal Patent Application (F	OTO 152\	
 Notice of References Cited (PTO-892) Dotice of Draftperson's Patent Drawing Review (PTO-948) 	_	ilormai Patent Application (F Summary (PTO-413),	10-102)	
3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/	_ Paper No	Paper No./Mail Date <u>06/01/04</u> . 7. \(\subseteq \text{Examiner's Amendment/Comment} \)		
Paper No./Mail Date			Mowanaa	
 Examiner's Comment Regarding Requirement for Deposit of Biological Material 	8. ☑ Examiners 9. ☐ Other	Statement of Reasons for A	Miowance	
		THURMAN K.) . Page NT Examiner NTER 1600	

DETAILED ACTION

Status of Application

Receipt of the Appeal Brief filed 02/19/04 is acknowledged.

Claims 1-29 are pending. Claims 1-29 are allowed.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Patrea L. Pabst on 05/28/04.

The application has been amended as follows:

In the Claims:

<u>Claim 1</u>, line 7, after the word "ingestion", the phrase "wherein the delayed release portion is achieved by coating a core or granulations with at least one delayed release control polymer" has been added.

Art Unit: 1615

Allowable Subject Matter

Claims 1-29 are allowed.

The following is an examiner's statement of reasons for allowance:

The instant invention is drawn to a biphasic antihistamine composition in daily oral uni-dosage or divided dosage form which comprises: (a) a therapeutically effective amount of a sedating antihistamine to inhibit antihistamine release for a duration of about 4 to 12 hours, and (b) a therapeutically effective amount of non-sedating antihistamine to inhibit antihistamine release for a duration of 10 to 20 hours, with a delayed release 6 to 10 hours after ingestion, wherein the delayed release portion is achieved by coating a core or granulations with at least one delayed release control polymer.

The primary reason for allowance is that the inclusion of the specific limitation of how the delayed release portion is achieved (i.e., by coating a core or granulations) was agreed upon in a telephone interview with Applicant(s) attorney. It was noted in the interview that the prior art does not teach a biphasic antihistamine composition comprising a delayed release non-sedating antihistamine in combination with a sedating antihistamine, whereby the delayed release portion is obtained by coating a core or granulations with at least one delayed release control polymer.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should

Application/Control Number: 10/012,202

Art Unit: 1615

preferably accompany the issue fee. Such submissions should be clearly labeled

"Comments on Statement of Reasons for Allowance."

Correspondence

Any inquiry concerning this communication or earlier communications from

the examiner should be directed to Humera N. Sheikh whose telephone number

is (571) 272-0604. The examiner can normally be reached on Monday through

Friday from 7:00A.M. to 4:30P.M.

If attempts to reach the examiner by telephone are unsuccessful, the

examiner's supervisor, Thurman Page, can be reached on (571) 272-0602. The

fax phone number for the organization where this application or proceeding is

assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application

or proceeding should be directed to the receptionist whose telephone number is

(703) 308-1235.

hns

June 01, 2003

THURMANIAN PAGE
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

Page 4